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613ong-Term Effectiveness and Safety of SES
Implantation for Coronary ISRrancesco Liistro, Massimo Fineschi, Simone Grotti, Paolo Angioli, Arcangelo Carrera, Kenneth Ducci,
ommaso Gori, Giovanni Falsini, Carlo Pierli, Leonardo Bolognese
his study by Liistro and colleagues evaluated the long-term clinical efficacy and safety of
irolimus-eluting stents (SES) for in-stent restenosis (ISR). Short-term results from the
RUE (Tuscany Registry Of Unselected In-Stent Restenosis) registry have previously been
ublished, and they showed a 5% rate of target lesion revascularization (TLR) and 1% stent
hrombosis (ST) at 9 months. At the 4-year follow-up, cardiac death occurred in 4.5% of
atients, nonfatal myocardial infarction in 3.2% of patients, and TLR in 11% of patients.
efinite ST occurred in 2% of patients and possible ST in 0.8% of patients. The clinical
enefit of SES implantation for bare-metal stent ISR is maintained at 4 years, with a low
LR rate and an overall incidence of ST of 0.7% per year.NTERVENTIONAL CARDIOLOGY617Bedside Monitoring of Enoxaparin Anticoagulationohanne Silvain, Farzin Beygui, Annick Ankri, Anne Bellemain-Appaix, Ana Pena, Olivier Barthelemy,
uillaume Cayla, Vanessa Gallois, Sophie Galier, Dominique Costagliola, Jean-Philippe Collet,
illes Montalescot
ilvain and colleagues evaluated the ability of the bedside test to identify patients treated with
noxaparin with insufficient anti-Xa activity. Whole blood Hemonox (International
echnidyne Corporation, Edison, New Jersey) clotting time (CT) was measured at baseline
nd 10 min after the intravenous administration of enoxaparin in patients receiving additional
noxaparin. These results were compared with plasma chromogenic anti-Xa activity level. The
hreshold value of 120 s for the Hemonox CT was associated with a 95% sensitivity and a
3% specificity to detect patients with an inadequate anti-Xa level (0.5 UI/ml). Hemonox
T appears to be a fast and reliable bedside test for detecting patients who are insufficiently
nticoagulated with enoxaparin for PCI.(continued on page A-23)
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EORONARY ARTERY DISEASE
627he Absence of Coronary Calcification Does Not
Exclude Obstructive Coronary Artery Disease CMElan Gottlieb, Julie M. Miller, Armin Arbab-Zadeh, Marc Dewey, Melvin E. Clouse, Leonardo Sara,
iroyuki Niinuma, David E. Bush, Narinder Paul, Andrea L. Vavere, John Texter, Jeffery Brinker,
oão A. C. Lima, Carlos E. Rochitte
he latest American Heart Association guidelines suggest that a calcium score (CS) of zero
ight exclude the need for coronary angiography among symptomatic patients. Gottlieb and
olleagues measured the CS in almost 300 patients referred for coronary angiography. About
ne-third of the patients had CS of zero, but 19% of these subjects had at least 1 50%
tenosis. In 64 totally occluded vessels, 13 (20%) had no calcium. The absence of coronary
alcification does not exclude obstructive stenosis or the need for revascularization among
atients referred for coronary angiography, and total coronary occlusion can occur in the
bsence of any detectable calcification.ditorial Comment: Rita F. Redberg, p. 635ORONARY ARTERY DISEASE
637ncreased Serum Levels of Vasoconstrictive and
Inflammatory Factors Link Emotional Stress to ACSte Wilbert-Lampen, Thomas Nickel, David Leistner, Denise Güthlin, Tomas Matis, Christoph Völker,
ebastian Sper, Helmut Küchenhoff, Stefan Kääb, Gerhard Steinbeck
ilbert-Lampen and colleagues documented higher rates of acute coronary syndromes (ACS)
uring the 2006 World Cup. For this report, serum levels of soluble CD40L (sCD40L),
oluble vascular cell adhesion molecule (sVCAM)-1, monocyte chemoattractant protein
MCP)-1, tumor necrosis factor (TNF)-, high-sensitivity C-reactive protein, regulated on
ctivation, normal T-cell expressed and secreted (RANTES), and endothelin (ET)-1 were
easured in patients who experienced an ACS during World Cup matches and were
ompared with patients who experienced an ACS not associated with emotional stress and
ith healthy volunteers. sCD40L, sVCAM-1, MCP-1, TNF-, and ET-1 were significantly
igher in study patients compared with the reference group. Stress-induced ACS is associated
ith a profound increase of inflammatory and vasoconstrictive mediators.
ditorial Comment: Karina W. Davidson, Matthew Burg, Daichi Shimbo, p. 643(continued on page A-26)
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tEART FAILURE645NT-proBNP–Guided Therapy Is Superior to Usual Careudolf Berger, Deddo Moertl, Sieglinde Peter, Roozbeh Ahmadi, Martin Huelsmann, Susan Yamuti,
runhilde Wagner, Richard Pacher
erger and colleagues investigated whether the addition of N-terminal pro–B-type natriuretic
eptide (NT-proBNP)-guided, intensive patient management (BM) to multidisciplinary care
MC) would improve outcomes in patients following a hospitalization due to heart failure
HF). After discharge, patients were randomized to BM, MC, or usual care (UC). MC
ncluded consultations from an HF specialist and home care by a specialized HF nurse. NT-
roBNP was used to guide up-titration of medications in addition to MC in the BM cohort.
fter 12 months, the BM group had the highest proportion of antineurohormonal triple-
herapy and fewer days of HF hospitalization. The combined end point of death or HF re-
ospitalization was lower in the BM group (37%) compared with the MC (50%) and UC
roups (65%). Compared with MC alone, knowledge of NT-proBNP levels can improve
linical outcomes.EART FAILURE
654frican-American Women Have a Higher Risk
for Developing Peripartum Cardiomyopathyindy B. Gentry, James K. Dias, Antonio Luis, Rakesh Patel, John Thornton, Guy L. Reed
he reported frequency of peripartum cardiomyopathy varies markedly between African and
on-African regions, but the risk factors for this disease are otherwise unknown. Gentry and
olleagues performed a case-control study at a large hospital that serves a racially
eterogeneous population. African-American women had a 15.7-fold higher relative risk of
eripartum cardiomyopathy than non-African Americans. African-American ethnicity
emained a significant risk factor for peripartum cardiomyopathy when other risk factors were
onsidered in multivariable and stratified analyses. African-American women have a
ignificantly higher risk of developing peripartum cardiomyopathy; further research is needed
o clarify the environmental and/or genetic factors that confer this risk.ALVULAR HEART DISEASE660Evidence of Widespread Vascular Changes in Subjects With BAV and ADikolaos Tzemos, Erik Lyseggen, Candice Silversides, Michal Jamorski, Jeffrey H. Tong, Paula Harvey,
ohn Floras, Samuel Siu
re-clinical studies have shown that endothelial nitric oxide synthase-deficient mice are
redisposed to develop bicuspid aortic valve (BAV) and aortic dilation (AD). Tzemos and
olleagues compared several indexes of vascular function in patients with BAV and AD, BAV
ithout AD, and healthy controls. The BAV subjects with AD had blunted brachial flow-
ediated vasodilation, higher carotid-femoral pulse wave velocity, and significantly higher
lasma levels of matrix metalloproteinase-2 compared with men with BAV and a nondilated
orta and with healthy controls. Subjects with BAV and AD have several vascular alterations
hat could introduce new targets for screening and perhaps for therapeutic intervention.Editorial Comment: S. Morteza Farasat, p. 669(continued on page A-32)
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sALVULAR HEART DISEASE671Evidence of Oxidative Stress, Permanent Myocyte Damage With MRustafa I. Ahmed, James D. Gladden, Silvio H. Litovsky, Steven G. Lloyd, Himanshu Gupta,
eidu Inusah, Thomas Denney, Jr, Pamela Powell, David C. McGiffin, Louis J. Dell’Italia
hmed and colleagues studied whether or not there was permanent cardiac damage from
solated mitral regurgitation (MR) even when subjects underwent mitral valve repair (MVR)
hen their ejection fraction was 60%. Twenty-seven patients with isolated MR had left
entricular (LV) biopsies taken at the time of MVR. Magnetic resonance imaging was
erformed pre-MVR and 6 months post-MVR and compared with healthy controls. After
VR, LV end-systolic volume index did not improve and remained enlarged compared with
ontrols. LV circumferential and longitudinal strain rates were both below normal post-MVR.
V biopsies demonstrated cardiomyocyte myofibrillar degeneration and increased xanthine
xidase and lipofuscin deposition. These imaging and immunohistochemistry results suggest
hat MR causes myocyte dysfunction, which does not fully reverse after MVR.FROM AROUND THE WORLD OCUS ON AFRICA680Cardiovascular Diseases in Africa: Challenges and Opportunitiesna Olga H. Mocumbi, Maria Beatriz Ferreira
heumatic heart disease, endomyocardial fibrosis, and peripartum cardiomyopathy are the
rimary causes of heart failure in sub-Saharan Africa. Although affecting several million
eople, these diseases have been relatively neglected by the medical and scientific
ommunities. The cardiovascular manifestations of infectious diseases, especially tuberculosis,
re also common, as are idiopathic disorders such as Takayasu’s arteritis and subvalvular left
entricular aneurysms. This paper by Mocumbi and Ferreira discusses the difficulties in the
iagnosis and management of “forgotten” conditions, and proposes strategies to stimulate
esearch on these conditions in the African context.YEAR IN CARDIOLOGY SERIES EAR IN CARDIOLOGY SERIES688The Year in Heart Failure. H. Wilson Tang, Gary S. Francis
ang and Francis review last year’s literature as it relates to heart failure (HF), from
athophysiology to destination therapy. Some of the highlighted areas include the association
etween modifiable risk factors and HF, the possible importance of micro-ribonucleic acid in
he pathophysiology of HF, and the disappointing results from the I-PRESERVE (Irbesartan
n Heart Failure with Preserved Ejection Fraction) trial. Papers showing improved outcomes
ith device-based therapy suggest that these interventions may be beneficial earlier in the
ourse of therapy. They conclude with the hope that in the near future there may be
ignificant advances in both our understanding of and in the arsenal for treating HF.
